Anna Dunphy
Paul McManus
Fusion is a Belfast based contract research organisation ( CRO ) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion s proprietary CDRx
TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutica
Investegate |OptiBiotix Health Announcements | OptiBiotix Health: SkinBioTherapeutics plc shareholding investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.